This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blanckaert, V. D. Articles by Meadows, G. G. Search for Related Content PubMed PubMed Citation Articles by Blanckaert, V. D. Articles by Meadows, G. G.

Differential Growth Factor Production, Secretion, and Response by High and Low Metastatic Variants of B16BL6 Melanoma¹

Department of Pharmaceutical Sciences and the Pharmacology/Toxicology Graduate Program, College of Pharmacy [C. A. E., G. G. M.], and Deparment of Genetics and Cell Biology [V. D. B., M. E. S.], Washington State University, Pullman, Washington 99164

Low levels of tyrosine and phenylalanine alter the metastatic phenotype of B16BL6 murine melanoma. In this study, we investigated expression and secretion of fibroblast growth factor-like (FGF-like) and transforming growth factor ß-like (TGFß-like) molecules as well as the biological effect of basic FGF (bFGF) and TGFß1 on high (NDP) and low (LTP) metastatic variants of B16BL6 melanoma. Both NDP and LTP cells expressed bFGF-like and TGFß-like polypeptides as detected by Western blot analysis. An M_r 29,000 bFGF-like form eluted from heparin-Sepharose by 0.6 M NaCl was found in extracts of both NDP and LTP cells. Elution at 0.6 M NaCl suggested that this M_r 29,000 form might be more closely related to FGF-5 than to bFGF. In addition, cell extracts of LTP, but not NDP cells, contained an M_r 47,000 monomeric bFGF-like form that was not retained on heparin-Sepharose. Three major specific immunoreactive forms of M_r 44,000, 36,000, and 29,000 were present in conditioned medium from NDP cells. The M_r 29,000 form present in the conditioned medium of NDP cells was retained on heparin-Sepharose. Only the M_r 44,000 and 36,000 FGF-like molecules were detected in conditioned medium from LTP cells, and they were also not retained on heparin-Sepharose. Anti-TGFß antibody that recognized both TGFß1 and TGFß2 detected 3 different TGFß-like forms (M_r 25,000, 23,000 and 22,000) in NDP and LTP cell extracts. Conditioned medium from NDP cells contained an M_r 38,000 form of TGFß; however, no immunoreactive forms were found in conditioned medium from LTP cells. Thus, the NDP-LTP differences in this melanoma system were primarily in growth factor secretion, not expression. The effect of exogenous bFGF and TGFß1 on proliferation of LTP and NDP cells was determined by [methyl-³H]thymidine uptake. bFGF stimulated proliferation of NDP cells; whereas, LTP cells exhibited no increase in proliferation. Both NDP and LTP cells responded to TGFß1. Proliferation of NDP cells was inhibited more by this growth factor than was proliferation of LTP cells. When NDP and LTP cells were incubated with 5 ng/ml TGFß1 and various amounts of bFGF, the effect of TGFß1 was masked. Antibody depletion of bFGF-like molecules from NDP conditioned medium resulted in the decreased proliferation of NDP cells but not LTP cells. Depletion of TGFß-like molecules resulted in increased proliferation of LTP cells but did not affect NDP cells. These data suggest (a) that bFGF-like and/or TGFß-like molecules are important markers of the metastatic phenotype of murine B16BL6 melanoma and (b) that the inability of B16BL6 melanoma cells to secrete FGF-like and TGFß-like molecules may contribute to a decreased metastatic capability.

¹ This investigation was supported by National Cancer Institute grant CA 42465.

² To whom request for reprints should be addressed, at Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Pullman, WA 99164-6510.

Received 2/22/93. Accepted 6/28/93.

This article has been cited by other articles:

				K. Kawakami, M. Terabe, M. Kioi, J. A. Berzofsky, and R. K. Puri Intratumoral Therapy with IL13-PE38 Results in Effective CTL-Mediated Suppression of IL-13R{alpha}2-Expressing Contralateral Tumors Clin. Cancer Res., August 1, 2006; 12(15): 4678 - 4686. [Abstract] [Full Text] [PDF]

				K. Kawakami, M. Terabe, M. Kawakami, J. A. Berzofsky, and R. K. Puri Characterization of a Novel Human Tumor Antigen Interleukin-13 Receptor {alpha}2 Chain. Cancer Res., April 15, 2006; 66(8): 4434 - 4442. [Abstract] [Full Text] [PDF]

				T. Hayashida, M. Ueda, K. Aiura, H. Tada, M. Onizuka, M. Seno, H. Yamada, and M. Kitajima Anti-angiogenic effect of an insertional fusion protein of human basic fibroblast growth factor and ribonuclease-1 Protein Eng. Des. Sel., July 1, 2005; 18(7): 321 - 327. [Abstract] [Full Text] [PDF]

				C. H. Poehlein, H.-M. Hu, J. Yamada, I. Assmann, W. G. Alvord, W. J. Urba, and B. A. Fox TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-{gamma} Double Knockout Effector T Cells J. Immunol., February 15, 2003; 170(4): 2004 - 2013. [Abstract] [Full Text] [PDF]

				H. Winter, H.-M. Hu, K. McClain, W. J. Urba, and B. A. Fox Immunotherapy of Melanoma: A Dichotomy in the Requirement for IFN-{{gamma}} in Vaccine-Induced Antitumor Immunity Versus Adoptive Immunotherapy J. Immunol., June 15, 2001; 166(12): 7370 - 7380. [Abstract] [Full Text] [PDF]

				J. Futami, M. Seno, M. Ueda, H. Tada, and H. Yamada Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor Protein Eng. Des. Sel., November 1, 1999; 12(11): 1013 - 1019. [Abstract] [Full Text] [PDF]

				H. Winter, H.-M. Hu, W. J. Urba, and B. A. Fox Tumor Regression After Adoptive Transfer of Effector T Cells Is Independent of Perforin or Fas Ligand (APO-1L/CD95L) J. Immunol., October 15, 1999; 163(8): 4462 - 4472. [Abstract] [Full Text] [PDF]

				S. Matsui, J. D. Ahlers, A. O. Vortmeyer, M. Terabe, T. Tsukui, D. P. Carbone, L. A. Liotta, and J. A. Berzofsky A Model for CD8+ CTL Tumor Immunosurveillance and Regulation of Tumor Escape by CD4 T Cells Through an Effect on Quality of CTL J. Immunol., July 1, 1999; 163(1): 184 - 193. [Abstract] [Full Text] [PDF]

				H.-M. Hu, W. J. Urba, and B. A. Fox Gene-Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T Cell Response from a Type 2 to a Type 1 Cytokine Profile J. Immunol., September 15, 1998; 161(6): 3033 - 3041. [Abstract] [Full Text] [PDF]